Publications
- Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis2012 | First Faculty of Medicine
- Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis2009 | First Faculty of Medicine
- Intramuscular Interferon Beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: design and preliminary results of a two-year double-blind, randomized, placebo-controlled studyPublication without faculty affiliation
- Tolerability of combine treatment with interferon beta and azathioprine in remitent MSPublication without faculty affiliation
- Interferon beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: preliminary clinical and MRI data from a two-year, double-blind, randomized, placebo-controlled studyPublication without faculty affiliation
- Intramuscular Interferon beta-1a, Azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis: 5-year clinical efficacy resultsPublication without faculty affiliation
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Multiple Sclerosis and Microbiome2022 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months2022 | First Faculty of Medicine
- To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection2022 | First Faculty of Medicine
Loading network view...